FibroBiologics, Inc. (FBLG)

FibroBiologics' stock price has declined significantly over the past six months. The company closed the third tranche of a Standby Equity Purchase Agreement and eliminated its convertible debt. Executive bonuses were approved, and the company reported increased losses in Q2 2025. Analysts have issued price targets ranging from $5.00 to $15.00 with a consensus "Moderate Buy" rating.

There is no specific information indicating demand seasonality for FibroBiologics, Inc.'s products and services. Demand is likely driven by disease prevalence, clinical trial outcomes, regulatory approvals, and market adoption.

FibroBiologics, Inc. is a clinical-stage biotechnology company focused on fibroblast-based therapies for chronic diseases. The company leverages its proprietary fibroblast platform and holds over 270 patents. Its pipeline includes CybroCell™ for degenerative disc disease, CYMS101 for multiple sclerosis, CYWC628 for diabetic foot ulcers, CYPS317 for psoriasis, and TCB190 and CYTER915. The company's focus areas include wound healing, certain cancers, orthopedics, and potential human longevity applications.

FibroBiologics, Inc. is headquartered in Houston, Texas, and has a subsidiary in Australia. A Phase 1/2 clinical trial for CYWC628 is planned in Australia in Q1 2026.

FibroBiologics has worked to enhance its brand reputation through scientific presentations and facility expansion. However, its reputation has likely been impacted by its significant stock price decline and concerns about its financial health.

The ownership structure of FibroBiologics, Inc. includes retail, institutional, and insider investors. Retail investors hold a substantial percentage of the company's stock. Major institutional owners include Vanguard Group Inc., Yorkville Advisors Global, LP and Millennium Management LLC. CEO Pete O'Heeron and Chief Scientific Officer Hamid Khoja have made insider purchases.